For two years compounded tirzepatide existed because the approved product did not: Mounjaro and Zepbound were on FDA's shortage list, and compounders were allowed to make copies. The shortage ended in December 2024, the legal basis ended in early 2025, and Lilly's own prices fell to a level that removed most of the cost argument. What is left in 2026 is a regulatory record, three waves of warning letters, FDA's adverse-event counts, and a price comparison that no longer favors the copy. This page sets those out from the FDA documents. It does not tell anyone which product to use; that belongs with a clinician, as our editorial standards say.
The two products
Zepbound is tirzepatide, approved by FDA under NDA 217806 on 2023-11-08 for chronic weight management, made by Lilly under manufacturing standards FDA inspects, sold in single-dose vials and a KwikPen. Compounded tirzepatide is a product a pharmacy makes from tirzepatide active ingredient it has bought, in a vial it fills and labels. FDA's own description of the category: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA compounding Q&A). Two kinds of compounder exist: 503A pharmacies, state-licensed and not subject to FDA's manufacturing-practice rules, and 503B outsourcing facilities, registered with FDA, inspected on a risk-based schedule and held to higher quality standards.
When the legal basis ended
Copying an approved drug is allowed only while that drug is on FDA's shortage list. Tirzepatide was added on 2022-12-15. FDA first removed it on 2024-10-02, was sued, re-evaluated, and on 2024-12-19 issued a declaratory order that "revokes and replaces FDA's October 2, 2024 decision" and "determines that the tirzepatide injection product shortage is resolved." The order acknowledges that "patients and prescribers may still see" local supply problems while stating that the national shortage is over.
FDA's policy statement then set the end dates for enforcement discretion, the period during which it would not act against compounders for shortage-dependent violations: for tirzepatide, 2025-02-18 for 503A pharmacies and 2025-03-19 for 503B facilities. Semaglutide's shortage was declared resolved on 2025-02-21, with discretion ending 2025-04-22 (503A) and 2025-05-22 (503B), and a court decision on 2025-04-24 confirmed the end. The same statement notes what FDA can still do at any time: "FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe."
What remains permitted is narrow. A compounder may make a product for a specific patient with a documented clinical need that the approved product cannot meet, and, under FDA's current policy as of 2026-04-01, "does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month." Four a month is not a business model. A service filling thousands is relying on something else.
What FDA has documented about the products
FDA's statement on unapproved GLP-1s, updated 2026-09-01, lists three problems (FDA).
Dosing errors. "Multiple reports of adverse events, some requiring hospitalization" tied to compounded semaglutide, arising from "patients measuring and self-administering incorrect doses" and from "health care professionals miscalculating doses of the drug", with symptoms including "nausea, vomiting, diarrhea, abdominal pain and constipation". FDA has also received "adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label." The mechanism is the vial: an approved pen delivers a fixed dose; a compounded vial is drawn up by the patient, and the concentration varies by pharmacy.
Salt forms. "Some semaglutide products sold by compounders may be the salt forms. These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs."
Fraud. "Fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label", including cases where "the compounding pharmacies identified on the labels of the products do not exist" and others where the named licensed pharmacy did not make the product.
The counts, as of 2026-05-31: "990 adverse event reports for compounded semaglutide" and "over 730 adverse event reports for compounded tirzepatide." For scale, the approved drugs generate far more reports in absolute terms because far more people take them; a 2025 analysis of FDA's adverse-event database found 65,974 tirzepatide reports from 2022 through the first quarter of 2025, with "incorrect dose administered" the most common category at 19,461, rising eightfold from 2022 to 2024 (Healthcare 2025, PMC12469573). That paper does not separate compounded from approved products, so it cannot say which the dosing errors belong to; FDA's own statement is the source that attributes reports to compounded products, and it does not give a rate.
In September 2025 FDA also created a "Green List" import alert that admits GLP-1 active ingredient only from facilities FDA has inspected or evaluated, with everything else detained; the announcement repeats the agency's finding of "dosing errors, use of unapproved salt forms and adverse events—some requiring hospitalization" with compounded versions (FDA, 2025-09-05).
The warning letters
FDA has now sent three coordinated waves of letters to telehealth companies selling compounded GLP-1s: "roughly 80 warning letters and 40 untitled letters" in September 2025, "30 warning letters" in March 2026, and "25 warning letters" in June 2026, per a law-firm summary dated 2026-06-18 (National Law Review). The letters are about marketing, and the summary groups the claims FDA objected to into six kinds: calling the product a "generic"; "express or implied claims that FDA approved, evaluated, or reviewed the compounded product"; equivalence claims that the product is "clinically proven" to match the approved drug; describing the source as an "FDA-approved" or "FDA-licensed" pharmacy; "branding, proprietary labeling, or label-like displays" implying the telehealth company is the compounder; and "exact same active ingredient(s)" statements.
One letter we opened shows the pattern. FDA's letter to NativeMed, dated 2026-06-08, cites the company for putting its logo on the tirzepatide label pictured on its site, "suggesting NativeMed was the compounder when in fact it was not", and for the claim that its compounded semaglutide contained "The same active ingredient in Ozempic® and Wegovy®", under the misbranding provisions of sections 502(a) and 502(bb) of the Food, Drug, and Cosmetic Act, with a 15-business-day response window (FDA warning letter). The active-ingredient claim is the one that matters for this comparison: FDA's position is that saying a compounded product has the same active ingredient as an approved drug implies an FDA evaluation that did not take place.
Cost, on 2026-09-05
| Product | Price per month | Source and date |
|---|---|---|
| Zepbound, LillyDirect self-pay, vial or KwikPen | $299 (2.5 mg), $399 (5 mg), $449 (7.5 mg to 15 mg) | Lilly's coverage and savings page, 2026-09-05 |
| Zepbound, commercial insurance with savings card | As little as $25, capped at $100 per month and $1,300 per year, card expires 2026-12-31 | Same page |
| Zepbound, list price | $1,088 | White House fact sheet, 2026-02-05 |
| Compounded tirzepatide | Not verifiable on the day: provider pages blocked our requests; third-party trackers quote roughly $200 to $500 | Not quoted |
The economics have inverted since 2024. Then, Zepbound listed above $1,000 with no self-pay program and compounded copies sold for a few hundred dollars; now Lilly sells the approved drug for $299 to $449 through its own pharmacy, and the White House's TrumpRx site routes to the same price. The largest telehealth seller of compounded semaglutide, Hims and Hers, settled litigation with Novo Nordisk on 2026-03-09 and, per its 2026-04-23 newsroom release, now offers Zepbound, Foundayo and Wegovy through the manufacturers' pharmacies rather than compounded versions (Hims and Hers newsroom). Our cost page has the full price table for every GLP-1 medicine.
What this page does not decide
Whether an individual patient with a documented need for a strength or formulation Lilly does not make should receive a compounded product is a clinical and legal question for the prescriber and the pharmacy, and the narrow exceptions exist for it. What this page reports is that the general case, a copy of Zepbound sold at scale because it is cheaper, lost its legal basis in early 2025, its price advantage in 2025 and 2026, and, in FDA's documented findings, carries risks the approved product does not.
Sources and dates
Opened 2026-09-05: FDA's declaratory order on the tirzepatide shortage (2024-12-19); FDA's statement clarifying policies for compounders; FDA's statement on unapproved GLP-1 drugs (updated 2026-09-01); FDA's Green List press release (2025-09-05); FDA's compounding Q&A; FDA's warning letter to NativeMed (2026-06-08); the National Law Review summary of the warning-letter waves (2026-06-18); the FAERS analysis in Healthcare 2025 (PMC12469573); Lilly's Zepbound coverage and savings page; the Hims and Hers newsroom release (2026-04-23); the White House TrumpRx fact sheet (2026-02-05). Provider price pages for compounded tirzepatide could not be opened and are not quoted. Corrections go to the contact page.